{"id":49053,"date":"2026-11-06T14:30:00","date_gmt":"2026-11-06T14:30:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/5091071_AE91071_0"},"modified":"2026-11-06T14:30:00","modified_gmt":"2026-11-06T14:30:00","slug":"oncoc4-reports-encouraging-phase-1-2-data-for-cesalatamig-monotherapy-in-previously-treated-non-small-cell-lung-cancer-at-sitc-2026","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=49053","title":{"rendered":"OncoC4 Reports Encouraging Phase 1\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026"},"content":{"rendered":"<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mmx.prnasia.com\/media\/MS1732834\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"prntac\"><b><i>\u2014 33% investigator-assessed<\/i><\/b><b><i>&nbsp;objective response rate and 90% disease control rate at 10 mg\/kg every three weeks in patients with PD-(L)1-resistant\/refractory NSCLC \u2014<\/i><\/b><\/p>\n<p class=\"prntac\"><b><i>\u2014 Preliminary efficacy and safety results support further development of cesalatamig monotherapy \u2014<\/i><\/b><\/p>\n<p><span class=\"legendSpanClass\">ROCKVILLE, Md.<\/span>, <span class=\"legendSpanClass\">Nov. 6, 2026<\/span> \/PRNewswire\/ &#8212; OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer, neurological and immunological diseases, today reported encouraging Phase 1\/2 results for <b>cesalatamig (AI-081)<\/b>, its investigational PD-1\/VEGF bispecific antibody, as monotherapy in patients with PD-(L)1-resistant\/refractory non-small cell lung cancer (NSCLC). The findings will be presented in a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Phoenix, Arizona.<\/p>\n<p>Results reported in the SITC abstract were derived from a pooled analysis of the global, multicenter, open-label BiPAVE-001 and BiPAVE-001 CN Phase 1\/2 studies. As of July 31, 2026, the safety population included 103 patients with NSCLC who had received at least one dose of cesalatamig monotherapy at 1, 3, 10 or 20 mg\/kg Q3W. Of these patients, 77 (75%) had non-squamous histology, 25 (24%) had squamous histology and one had unknown histology. 77% of patients had a baseline ECOG performance status of 1. The median number of prior therapy lines was two, and 42% of patients had received three or more prior lines.&nbsp; The safety profile was comparable between patients with squamous and non-squamous histology. The cesalatamig monotherapy is well tolerated at all dose levels.<\/p>\n<p>Among 55 efficacy-evaluable patients with PD-(L)1 resistant\/refractory NSCLC, cesalatamig monotherapy demonstrated dose-dependent antitumor activity. At 1 mg\/kg (10 patients), 3 mg\/kg (24 patients) and 10 mg\/kg (21 patients) Q3W, investigator-assessed objective response rates (ORR) were 10%, 21% and 33%, respectively; disease control rates (DCR) were 40%, 67% and 90%, respectively.&nbsp; Responses to cesalatamig monotherapy were observed across PD-L1 expression levels. Exposure-response analyses support selection of 10 mg\/kg Q3W as the dose for further development.<\/p>\n<p>&#8220;Patients whose NSCLC progresses after immunotherapy and chemotherapy have limited effective treatment options,&#8221; said <b>Kai He, MD, PhD<\/b>, principal investigator of the US BiPAVE-001 trial and the presenter of this study. &#8220;The responses and disease control observed with cesalatamig monotherapy are encouraging. Together with the manageable safety profile observed in these studies, these findings support further clinical evaluation in this setting.&#8221;<\/p>\n<p>&#8220;These findings strengthen the rationale for advancing cesalatamig monotherapy in previously treated NSCLC,&#8221; said Yang Liu, PhD, Co-founder, Chief Executive Officer and Chief Scientific Officer of OncoC4. &#8220;The clinical results and exposure-response analyses support the selection of 10 mg\/kg every three weeks as the dose for our planned pivotal study and provide a clear path forward for the continued development of cesalatamig in this setting.&#8221;<\/p>\n<p><b>Presentation Information<\/b><\/p>\n<p><b>Title:<\/b> <i>Safety and Efficacy of Cesalatamig, a Novel PD-1\/VEGF Bispecific Antibody, as Monotherapy in PD-(L)1\u2013Resistant\/Refractory NSCLC: Results from Global, Multicenter, Open-Label Phase 1\/2 Studies<\/i><\/p>\n<p><b>Abstract:<\/b> #1187 (late-breaking oral presentation)<br \/><b>Presenter:<\/b> Kai He, MD, PhD<br \/><b>Date:<\/b> November 7, 2026<br \/><b>Meeting:<\/b> 41st Annual Meeting of the Society for Immunotherapy of Cancer, Phoenix, Arizona<br \/><b>Session:<\/b> Clinical Oral Abstract Session 2, beginning at 1:45 PM MST<\/p>\n<p><b>About Cesalatamig<\/b><\/p>\n<p>Cesalatamig (AI-081) is an investigational, tetravalent PD-1\/VEGF bispecific antibody designed to promote cooperative interactions between PD-1 and VEGF blockade in the tumor microenvironment. It combines high-affinity binding with Fc-silencing modifications intended to avoid depletion of PD-1-positive effector T cells. Cesalatamig is being evaluated as monotherapy and in combination with standard of care in the ongoing BiPAVE-001 clinical program. In September 2026, the U.S. FDA granted cesalatamig Fast Track designation for NSCLC that has progressed after concurrent or sequential PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.<\/p>\n<p><b>About BiPAVE-001<\/b><\/p>\n<p>BiPAVE-001 (NCT06635785) and BiPAVE-001 CN (CTR20253261) are ongoing Phase 1\/2 clinical trials evaluating the safety, pharmacokinetics, and efficacy of cesalatamig (AI-081), a bispecific antibody targeting PD-1 and VEGF, in patients with advanced solid tumors. OncoC4 is conducting these studies in the United States and China, respectively. Part A is the first-in-human Phase 1 dose-escalation and dose-expansion portion in patients with advanced solid tumors. Part B is the Phase 2 portion and includes dose-optimization trials evaluating AI-081 as monotherapy or in combination with standard of care in selected indications.<\/p>\n<p><b>About OncoC4<\/b><\/p>\n<p>Headquartered in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologics for the treatment of cancer, neurological and immunological diseases. OncoC4&#8217;s pipeline features assets with first-in-class and best-in-class potential targeting both novel and well-validated targets across oncology and immunological diseases. Among them, cesalatamig is a wholly owned and highly differentiated PD-1\/VEGF bispecific antibody currently undergoing rapid global clinical development in multiple oncology indications. Tasafustobart (ONC-841) is a first-in-class anti-SIGLEC-10 antibody currently in a Phase 2 trial for oncology indications and a Phase 1 trial for neurodegenerative diseases. In addition, OncoC4 recently initiated a first-in-human trial of ONC-783, a first-in-class T cell engager targeting a novel CD24 epitope selectively expressed across a broad spectrum of human cancers, including solid tumors and hematological malignancies, in the United States. OncoC4 has a strategic collaboration with BioNTech to co-develop gotistobart (BNT316\/ONC-392), a tumor microenvironment-selective Treg depletion candidate targeting CTLA-4, in multiple solid tumor indications, including an ongoing pivotal clinical trial in squamous non-small cell lung cancer.<\/p>\n<p>More information: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4816232-1&amp;h=2547793359&amp;u=https%3A%2F%2Fwww.oncoc4.com%2F&amp;a=www.oncoc4.com\" target=\"_blank\" rel=\"nofollow\">www.oncoc4.com<\/a><\/p>\n<p><b>CONTACTS<\/b><\/p>\n<p>Media Relations<br \/>Helen Schiltz<br \/><a href=\"mailto:media@oncoc4.com\" target=\"_blank\" rel=\"nofollow\">media@oncoc4.com<\/a><\/p>\n<p>Investor Relations<br \/>Ryan Cui<br \/><a href=\"mailto:ir@oncoc4.com\" target=\"_blank\" rel=\"nofollow\">ir@oncoc4.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u2014 33% investigator-assessed&nbsp;objective response rate and 90% disease control rate at 10 mg\/kg every three weeks in patients with PD-(L)1-resistant\/refractory NSCLC \u2014 \u2014 Preliminary efficacy and safety results support further development of cesalatamig monotherapy \u2014 ROCKVILLE, Md., Nov. 6, 2026 \/PRNewswire\/ &#8212; OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer, neurological [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-49053","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OncoC4 Reports Encouraging Phase 1\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026 - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=49053\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncoC4 Reports Encouraging Phase 1\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026 - My Blog\" \/>\n<meta property=\"og:description\" content=\"\u2014 33% investigator-assessed&nbsp;objective response rate and 90% disease control rate at 10 mg\/kg every three weeks in patients with PD-(L)1-resistant\/refractory NSCLC \u2014 \u2014 Preliminary efficacy and safety results support further development of cesalatamig monotherapy \u2014 ROCKVILLE, Md., Nov. 6, 2026 \/PRNewswire\/ &#8212; OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer, neurological [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=49053\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T14:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnasia.com\/media\/MS1732834\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"OncoC4 Reports Encouraging Phase 1\\\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026\",\"datePublished\":\"2026-11-06T14:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053\"},\"wordCount\":867,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnasia.com\\\/media\\\/MS1732834\\\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053\",\"name\":\"OncoC4 Reports Encouraging Phase 1\\\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026 - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnasia.com\\\/media\\\/MS1732834\\\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600\",\"datePublished\":\"2026-11-06T14:30:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnasia.com\\\/media\\\/MS1732834\\\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600\",\"contentUrl\":\"https:\\\/\\\/mmx.prnasia.com\\\/media\\\/MS1732834\\\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=49053#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncoC4 Reports Encouraging Phase 1\\\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OncoC4 Reports Encouraging Phase 1\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026 - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=49053","og_locale":"en_US","og_type":"article","og_title":"OncoC4 Reports Encouraging Phase 1\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026 - My Blog","og_description":"\u2014 33% investigator-assessed&nbsp;objective response rate and 90% disease control rate at 10 mg\/kg every three weeks in patients with PD-(L)1-resistant\/refractory NSCLC \u2014 \u2014 Preliminary efficacy and safety results support further development of cesalatamig monotherapy \u2014 ROCKVILLE, Md., Nov. 6, 2026 \/PRNewswire\/ &#8212; OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer, neurological [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=49053","og_site_name":"My Blog","article_published_time":"2026-11-06T14:30:00+00:00","og_image":[{"url":"https:\/\/mmx.prnasia.com\/media\/MS1732834\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=49053#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49053"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"OncoC4 Reports Encouraging Phase 1\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026","datePublished":"2026-11-06T14:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49053"},"wordCount":867,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49053#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnasia.com\/media\/MS1732834\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=49053","url":"https:\/\/transmediavictoria.net.au\/?p=49053","name":"OncoC4 Reports Encouraging Phase 1\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026 - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49053#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49053#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnasia.com\/media\/MS1732834\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600","datePublished":"2026-11-06T14:30:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=49053#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=49053"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=49053#primaryimage","url":"https:\/\/mmx.prnasia.com\/media\/MS1732834\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600","contentUrl":"https:\/\/mmx.prnasia.com\/media\/MS1732834\/OncoC4-Logo.jpg?id=OA3062523&amp;p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=49053#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"OncoC4 Reports Encouraging Phase 1\/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/49053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49053"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/49053\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}